Strain-specific Immunity to Plasmodium vivax malaria

对间日疟原虫疟疾的菌株特异性免疫

基本信息

项目摘要

DESCRIPTION (provided by applicant): Plasmodium vivax malaria contributes to a large burden of malaria morbidity owing to its widespread global distribution, the increasing prevalence of drug-resistant strains and most importantly, infections with Pv cause severe clinical syndromes. Plasmodium vivax accounts for 12.4% of infections acquired in Africa and 70-90% of infections acquired in Asia and the Americas. More cases of Pv are now reported than any other malaria species for active duty or returning soldiers. Because of increasing drug resistance to Pv, lethal cases and replapsing behavior of Pv, development of Pv vaccine is a major priority of the Military Infectious Disease Research Program. One the leading Pv vaccine candidates is P. vivax Duffy binding protein region II (PvDBPII). This protein is expressed at the parasite's cellular surface and binds the host red cell's Duffy antigen (Fy) that facilitates erythrocyte invasion. Other human malaria such as P. falciparum, have several different Duffy Binding Protein-like genes that facilitate the use o alternative receptors for merozoite invasion, however the almost exclusive dependence of PvDBPII and Duffy antigen for Pv invasion of erythrocytes a critical weakness and makes the Pv DBP ligand an ideal target for vaccine development. Substantial challenges remain for use PvDBPII as a vaccine, including its high degree of polymorphism, its weak immunogenicity and a lack of understanding as regards to the specific portion of the molecule engendering the strongest blocking or protective responses. This proposal builds on observations from our current project. First, we have identified a subset of individuals in endemic areas who acquire high titers of functional antibodies described above that block binding to multiple PvDBPII variants. Mapping of the functional human Abs to specific regions of PvDBPII may help to identify a strain-transcending vaccine. Second, polyclonal and monoclonal antibodies generated in different animals that block binding of PvDBPII to Fy preferentially recognize a relatively conserved sub-domain of PvDBPII that could facilitate development of a vaccine. Third, we have shown that the major polymorphism in Fy (Fyb¿Fya, Asp42Gly) is associated with both diminished binding of PvDBPII and a reduced risk of clinical Pv in humans. We found that both naturally acquired and artificially induced Abs directed to PvDBPII more effectively blocked its binding to Fya as compared to Fyb erythrocytes, indicating host Fy genotype may be important vaccine efficacy. Aim 1. To identify epitopes on PvDBPII recognized by strain-transcending neutralizing antibodies. Aim 2. To develop vaccine approaches to elicit strain-transcending blocking/invasion inhibitory antibodies to PvDBPII. Aim 3. To determine the role of the Duffy Fya as compared to Fyb phenotype in functional immune responses to PvDBPII in vitro and in vivo.
描述(由申请人提供): 间日疟原虫疟疾由于其广泛的全球分布、耐药菌株的日益流行以及最重要的是,Pv感染导致严重的临床综合征,造成了疟疾发病率的巨大负担。间日疟原虫占非洲获得性感染的12.4%,占亚洲和美洲获得性感染的70-90%。现在报告的现役或返回的士兵中的Pv病例比任何其他疟疾种类都多。由于PV耐药性的增加、致死病例的增加和PV的再感染行为,PV疫苗的开发是军事传染病研究计划的主要优先事项。间日疟原虫达菲结合蛋白区II(PvDBPII)是一种领先的Pv疫苗候选疫苗。这种蛋白质在寄生虫的细胞表面表达,并结合宿主红细胞的达菲抗原(Fy),促进红细胞入侵。其他人疟疾如恶性疟原虫具有几种不同的Duffy结合蛋白样基因,其促进使用用于裂殖子侵入的替代受体,然而,Pv侵入红细胞几乎完全依赖于PvDBPII和Duffy抗原,这是一个关键的弱点,并使Pv DBP配体成为疫苗开发的理想靶标。 使用PvDBPII作为疫苗仍然存在巨大的挑战,包括其高度多态性,其弱免疫原性以及缺乏对产生最强阻断或保护性应答的分子的特定部分的理解。这一建议建立在我们目前项目的观察基础上。首先,我们已经鉴定了流行地区的一个个体子集,其获得高滴度的上述功能性抗体,其阻断与多种PvDBPII变体的结合。将功能性人抗体定位到PvDBPII的特定区域可能有助于鉴定菌株超越疫苗。第二,在不同动物中产生的阻断PvDBPII与Fy结合的多克隆和单克隆抗体优先识别PvDBPII的相对保守的亚结构域,其可以促进疫苗的开发。第三,我们已经表明,Fy的主要多态性(Fyb <$Fya,Asp 42 Gly)与PvDBPII结合减少和人类临床Pv风险降低有关。我们发现,与Fyb红细胞相比,天然获得的和人工诱导的针对PvDBPII的Ab更有效地阻断其与Fya的结合,表明宿主Fy基因型可能是重要的疫苗功效。目标1。鉴定PvDBPII上可被跨菌株中和抗体识别的表位。目标二。开发疫苗方法以引发针对PvDBPII的菌株超越阻断/侵袭抑制抗体。目标3.确定Duffy Fya与Fyb表型相比在体外和体内对PvDBPII的功能性免疫应答中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher L King其他文献

Broad immunogenicity to prior SARS-CoV-2 strains and JN.1 variant elicited by XBB.1.5 vaccination in nursing home residents
在疗养院居民中接种 XBB.1.5 疫苗对先前的 SARS-CoV-2 毒株和 JN.1 变异体具有广泛的免疫原性
  • DOI:
    10.1101/2024.03.21.24303684
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yasin Abul;Clare Nugent;Igor Vishnepolskiy;Tiffany Wallace;Evan Dickerson;Laurel Holland;Iva Esparza;Mandi Winkis;Kazi Tanvee Wali;Philip A Chan;Rosa R. Baier;Amy Recker;Matthew Kaczynski;Shreya Kamojjala;Alexander Pralea;Hailee Rice;Olubunmi Osias;Oladayo A. Oyebanji;Olajide J. Olagunju;Yi Cao;Chia Jung Li;Alex Roederer;Walther M. Pfeifer;Christopher L King;J. Bosch;Aman Nanda;Lynn McNicoll;Nadia Mujahid;S. Raza;Rohit Tyagi;Brigid M Wilson;Elizabeth M. White;David H Canaday;Stefan Gravenstein;A. Balazs
  • 通讯作者:
    A. Balazs
Evaluating PK/PD Relationship of CNS Drug by Using Liquid Chromtography/ Tandem Mass Spectrometry Coupled to In Vivo Microdialysis
使用液相色谱/串联质谱联用体内微透析评估中枢神经系统药物的 PK/PD 关系
  • DOI:
    10.5772/33100
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Y. Qu;L. Olson;X. Jiang;L. Aluisio;Christopher L King;E. Jones;T. Lovenberg
  • 通讯作者:
    T. Lovenberg

Christopher L King的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher L King', 18)}}的其他基金

Defining targets of protective immunity to vivax malaria using human monoclonal antibodies
使用人单克隆抗体确定间日疟疾的保护性免疫目标
  • 批准号:
    10353401
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies
使用人单克隆抗体确定间日疟疾的保护性免疫目标
  • 批准号:
    10132239
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies
使用人单克隆抗体确定间日疟疾的保护性免疫目标
  • 批准号:
    10599119
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Early Drivers of Humoral Immunity to SARS-CoV-2 Infections
SARS-CoV-2 感染体液免疫的早期驱动因素
  • 批准号:
    10222232
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Early Drivers of Humoral Immunity to SARS-CoV-2 Infections
SARS-CoV-2 感染体液免疫的早期驱动因素
  • 批准号:
    10680626
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies
使用人单克隆抗体确定间日疟疾的保护性免疫目标
  • 批准号:
    9973847
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Early Drivers of Humoral Immunity to SARS-CoV-2 Infections
SARS-CoV-2 感染体液免疫的早期驱动因素
  • 批准号:
    10855050
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Defining targets of protective immunity in Plasmodium vivax using human monoclonal antibodies
使用人单克隆抗体确定间日疟原虫保护性免疫的目标
  • 批准号:
    10651591
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Pathogenesis
发病
  • 批准号:
    8494538
  • 财政年份:
    2013
  • 资助金额:
    --
  • 项目类别:
Pathogenesis
发病
  • 批准号:
    8293255
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了